# Alkem Laboratories (NSE: ALKEM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ALKEM · Pivot · prices to 22 Oct 2026

Alkem Laboratories (NSE: ALKEM) closed at ₹4,972.00 on 22 Oct 2026, down 0.58% on the day. With a market capitalisation of ₹59,448 Cr, it ranks 170th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 25.8× trailing earnings, against a return on equity of 16.7% in FY26. Over the past year the share price has fallen 9.6%. Its 52-week range is ₹4,811.00 (22 Oct 2026) to ₹5,933.50 (13 Jan 2026); the last close is 16.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹3,603 Cr (+14.6% year on year) and net profit ₹252 Cr (−22.1%), on a consolidated basis. Promoters held 49.70% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹4,972.00 |
| Market cap | ₹59,448 Cr |
| P/E (trailing) | 25.8 |
| ROE | 16.7% (FY26) |
| ROCE | 19.9% (FY26) |
| Debt to equity | 0.12 |
| 52-week high | ₹5,933.50 (13 Jan 2026) |
| 52-week low | ₹4,811.00 (22 Oct 2026) |
| 1-year return | −9.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹3,603 Cr | +14.6% | ₹252 Cr | −22.1% | ₹19.77 |
| Q3 FY26 | ₹3,737 Cr | +10.7% | ₹654 Cr | +2.0% | ₹53.19 |
| Q2 FY26 | ₹4,001 Cr | +17.2% | ₹780 Cr | +11.1% | ₹63.99 |
| Q1 FY26 | ₹3,371 Cr | +11.2% | ₹668 Cr | +21.5% | ₹55.56 |
| Q4 FY25 | ₹3,144 Cr | +7.1% | ₹323 Cr | +6.1% | ₹25.57 |
| Q3 FY25 | ₹3,374 Cr | +1.5% | ₹641 Cr | +6.0% | ₹52.34 |
| Q2 FY25 | ₹3,415 Cr | −0.7% | ₹702 Cr | +14.2% | ₹57.60 |
| Q1 FY25 | ₹3,032 Cr | +2.2% | ₹550 Cr | +91.2% | ₹45.60 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹12,965 Cr | ₹2,216 Cr |
| FY24 | ₹12,668 Cr | ₹1,811 Cr |
| FY23 | ₹11,599 Cr | ₹1,007 Cr |
| FY22 | ₹10,634 Cr | ₹1,680 Cr |
| FY21 | ₹8,865 Cr | ₹1,618 Cr |
| FY20 | ₹8,344 Cr | ₹1,149 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 49.70%
- Foreign institutions: 10.42%
- Domestic institutions: 22.63%
- Non-institutions: 17.25%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Glenmark Pharmaceuticals](https://app.pivotnow.in/stock/GLENMARK) | ₹2,196.40 | ₹61,983 Cr | 45.5 | — |
| [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | ₹647.20 | ₹56,415 Cr | 101.1 | — |
| [Fortis Healthcare](https://app.pivotnow.in/stock/FORTIS) | ₹720.15 | ₹54,368 Cr | 52.3 | — |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | ₹332.85 | ₹54,244 Cr | 117.6 | — |
| [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,445.00 | ₹54,069 Cr | 34.8 | — |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,932.90 | ₹49,038 Cr | 43 | — |

## Questions and answers

### What is the share price of Alkem Laboratories today?

Alkem Laboratories (NSE: ALKEM) last closed at ₹4,972.00 on 22 Oct 2026. Its 52-week high is ₹5,933.50 and its 52-week low is ₹4,811.00.

### What is the market cap of Alkem Laboratories?

Alkem Laboratories' market capitalisation is ₹59,448 Cr (₹59,448 Cr) at the 22 Oct 2026 close, ranking 170th among the NSE companies Pivot tracks.

### What is the P/E ratio of Alkem Laboratories?

Alkem Laboratories trades at a trailing P/E of 25.8. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 52.3.

### What is the ROE and ROCE of Alkem Laboratories?

Return on equity was 16.7% in FY26 and return on capital employed was 19.9% in FY26 (consolidated figures).

### Is Alkem Laboratories a debt-free company?

No. Alkem Laboratories' debt-to-equity ratio was 0.12 in FY26, with total debt of ₹492 Cr.

### What were Alkem Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Alkem Laboratories reported revenue of ₹3,603 Cr, +14.6% year on year, and net profit of ₹252 Cr, −22.1% year on year.

### How has Alkem Laboratories stock performed over the last year?

Alkem Laboratories' share price has fallen 9.6% over the past year, −10.8% over three months and −7.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Alkem Laboratories?

As of 30 Jun 2026: promoters 49.70%, foreign institutions 10.42%, domestic institutions 22.63%, non-institutions 17.25%.

### Who are Alkem Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Alkem Laboratories by market cap are Glenmark Pharmaceuticals, Aster DM Health, Fortis Healthcare, Biocon, Abbott India and IPCA Laboratories.

### Is Alkem Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Alkem Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALKEM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.